吉林长龙药业(08049)披露2026年中期业绩：营收4.35亿元净利润1.23亿元同比增19%

公告速递

Aug 14

1. 吉林长龙药业(08049)于2026年8月14日公布截至2026年6月30日止六个月未经过审的中期业绩。期内，集团实现营业额4.35亿元，较2025年同期的4.39亿元减少0.1%。

2. 受益于销售成本下降及毛利改善，期内毛利录得3.65亿元，高于上年同期的3.62亿元；毛利率约83.9%。

3. 经营溢利为1.52亿元，较2025年同期的1.24亿元增加28.1%。财务费用为0.17亿元，上年同期为0.09亿元。

4. 期内税前溢利1.50亿元，较上年同期的1.23亿元增加0.27亿元；所得税费用为0.27亿元。归属于公司股东的净利润为1.23亿元，较上年同期增加1,983.2万元。基本每股收益为0.2192元，上年同期为0.1838元。

5. 销售及分销成本1.98亿元，较上年同期的2.03亿元减少；占营业额比例由上年同期的46%降至45%。行政开支0.43亿元，低于上年同期的0.45亿元。

6. 截至2026年6月30日，集团现金及现金等价物余额2.34亿元；期内无银行借款，资本负债率为0%。总权益18.11亿元，较2025年12月31日的16.88亿元增加1.23亿元。

7. 董事会建议不派发中期股息。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1115303410"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115303410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115303410?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-14 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115303410","market":"sh","top_or_hot":-1,"title":"吉林长龙药业(08049)披露2026年中期业绩：营收4.35亿元 净利润1.23亿元同比增19%","media":"公告速递","content":"<p>1. 吉林长龙药业(08049)于2026年8月14日公布截至2026年6月30日止六个月未经过审的中期业绩。期内，集团实现营业额4.35亿元，较2025年同期的4.39亿元减少0.1%。</p>\n<p>2. 受益于销售成本下降及毛利改善，期内毛利录得3.65亿元，高于上年同期的3.62亿元；毛利率约83.9%。</p>\n<p>3. 经营溢利为1.52亿元，较2025年同期的1.24亿元增加28.1%。财务费用为0.17亿元，上年同期为0.09亿元。</p>\n<p>4. 期内税前溢利1.50亿元，较上年同期的1.23亿元增加0.27亿元；所得税费用为0.27亿元。归属于公司股东的净利润为1.23亿元，较上年同期增加1,983.2万元。基本每股收益为0.2192元，上年同期为0.1838元。</p>\n<p>5. 销售及分销成本1.98亿元，较上年同期的2.03亿元减少；占营业额比例由上年同期的46%降至45%。行政开支0.43亿元，低于上年同期的0.45亿元。</p>\n<p>6. 截至2026年6月30日，集团现金及现金等价物余额2.34亿元；期内无银行借款，资本负债率为0%。总权益18.11亿元，较2025年12月31日的16.88亿元增加1.23亿元。</p>\n<p>7. 董事会建议不派发中期股息。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉林长龙药业(08049)披露2026年中期业绩：营收4.35亿元 净利润1.23亿元同比增19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉林长龙药业(08049)披露2026年中期业绩：营收4.35亿元 净利润1.23亿元同比增19%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-08-14 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>1. 吉林长龙药业(08049)于2026年8月14日公布截至2026年6月30日止六个月未经过审的中期业绩。期内，集团实现营业额4.35亿元，较2025年同期的4.39亿元减少0.1%。</p>\n<p>2. 受益于销售成本下降及毛利改善，期内毛利录得3.65亿元，高于上年同期的3.62亿元；毛利率约83.9%。</p>\n<p>3. 经营溢利为1.52亿元，较2025年同期的1.24亿元增加28.1%。财务费用为0.17亿元，上年同期为0.09亿元。</p>\n<p>4. 期内税前溢利1.50亿元，较上年同期的1.23亿元增加0.27亿元；所得税费用为0.27亿元。归属于公司股东的净利润为1.23亿元，较上年同期增加1,983.2万元。基本每股收益为0.2192元，上年同期为0.1838元。</p>\n<p>5. 销售及分销成本1.98亿元，较上年同期的2.03亿元减少；占营业额比例由上年同期的46%降至45%。行政开支0.43亿元，低于上年同期的0.45亿元。</p>\n<p>6. 截至2026年6月30日，集团现金及现金等价物余额2.34亿元；期内无银行借款，资本负债率为0%。总权益18.11亿元，较2025年12月31日的16.88亿元增加1.23亿元。</p>\n<p>7. 董事会建议不派发中期股息。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08049","symbol_name":"吉林长龙药业","start_time":0,"source_url":"","article_id":"1115303410","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115303410","pubTimestamp":1786717870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"期内，集团实现营业额4.35亿元，较2025年同期的4.39亿元减少0.1%。归属于公司股东的净利润为1.23亿元，较上年同期增加1,983.2万元。行政开支0.43亿元，低于上年同期的0.45亿元。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"08049":"吉林长龙药业"},"translate_title":"Jilin Changlong Pharmaceutical (08049) disclosed its 2026 interim results: revenue of 435 million yuan, net profit of 123 million yuan, a year-on-year increase of 19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08049":1},"content_text":"1. 吉林长龙药业(08049)于2026年8月14日公布截至2026年6月30日止六个月未经过审的中期业绩。期内，集团实现营业额4.35亿元，较2025年同期的4.39亿元减少0.1%。\n2. 受益于销售成本下降及毛利改善，期内毛利录得3.65亿元，高于上年同期的3.62亿元；毛利率约83.9%。\n3. 经营溢利为1.52亿元，较2025年同期的1.24亿元增加28.1%。财务费用为0.17亿元，上年同期为0.09亿元。\n4. 期内税前溢利1.50亿元，较上年同期的1.23亿元增加0.27亿元；所得税费用为0.27亿元。归属于公司股东的净利润为1.23亿元，较上年同期增加1,983.2万元。基本每股收益为0.2192元，上年同期为0.1838元。\n5. 销售及分销成本1.98亿元，较上年同期的2.03亿元减少；占营业额比例由上年同期的46%降至45%。行政开支0.43亿元，低于上年同期的0.45亿元。\n6. 截至2026年6月30日，集团现金及现金等价物余额2.34亿元；期内无银行借款，资本负债率为0%。总权益18.11亿元，较2025年12月31日的16.88亿元增加1.23亿元。\n7. 董事会建议不派发中期股息。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}